Eli Lilly unveils pivotal data from the star of its Dermira buyout. But can it rival Dupixent in atopic dermatitis?
It’s been just over a year and a half since Eli Lilly shelled out $1.1 billion for Dermira and its old Roche castoff lebrikizumab for atopic dermatitis. Now the pharma says it has the Phase III results it was looking for — but are they good enough to rival Regeneron and Sanofi’s blockbuster Dupixent?
According to topline results, the IL-13 inhibitor helped more than half of adults and adolescents in two trials achieve at least 75% clearance of their eczema (measured by the Eczema Area and Severity Index). The studies met the primary and key secondary endpoints at Week 16, Eli Lilly said on Monday, including skin clearance and itch improvement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.